Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2491
    -0.0020 (-0.16%)
     

  • Bitcoin GBP

    51,113.21
    -931.20 (-1.79%)
     

  • CMC Crypto 200

    1,383.71
    -12.82 (-0.92%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher

Zacks Equity Research
Updated

Sangamo Therapeutics, Inc. SGMO was a big mover last session, as the company saw its shares rise nearly 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $11.60 to $14.50 in the past one-month time frame.

The move came after the company reported that its Hunter syndrome treatment witnessed a new mileage when the first patient had been dosed in a phase 1/2 trial to evaluate the potential for its gene-editing technology.

Though the company has seen one positive estimate revision over the past few weeks, the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Sangamo Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive.

Sangamo Therapeutics, Inc. Price

Sangamo Therapeutics, Inc. Price | Sangamo Therapeutics, Inc. Quote

ADVERTISEMENT

Another stock worth considering in the Medical - Biomedical and Genetics industry is Myriad Genetics, Inc. MYGN which carries a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.

Is SGMO going up? Or down? Predict to see what others think: Up or Down

Zacks’ Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.

Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.

Click here for Zacks' private trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report
 
Sangamo Therapeutics, Inc. (SGMO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research